# Strategic Feedback — GPT-5.4 (R2)

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.4
**Timestamp:** 2026-04-03T20:23:53.553636
**Route:** OpenRouter + LaTeX
**Tokens:** 9132 in / 3220 out
**Response SHA256:** 4fcd17110013c20e

---

## 1. THE ELEVATOR PITCH

This paper argues that an important part of the opioid crisis was not just how many pills were shipped, but how strong those pills were. Using the expansion of one major generic manufacturer's high-dose oxycodone product line, it shows that generic competition changed the geographic composition of opioid potency, suggesting that ordinary product-line decisions in pharmaceutical markets can have large public-health consequences.

A busy economist should care because this is potentially a fresh way to think about both the opioid epidemic and generic-drug competition: firms may compete on product attributes that matter for harm, not just on price and quantity.

### Does the paper articulate this pitch clearly in the first two paragraphs?
Mostly yes, and better than many papers. The opening move—“the literature treats generic opioid supply as homogeneous; this paper shows potency mattered”—is sharp and intelligible. The problem is that the introduction then quickly turns into an empirical-strategy memo. By paragraph 3, the paper is no longer selling a question about the world; it is selling a design.

### What should the first two paragraphs say instead?
The first two paragraphs should lean harder into the substantive claim and the stakes:

> The first wave of the opioid crisis is usually described as a story about volume: too many pills reached too many places. But for addiction risk, diversion, and overdose, composition matters too. A market flooded with stronger pills is different from a market flooded with weaker ones, yet economists have largely treated generic opioid supply as homogeneous.  
>   
> This paper shows that the generic oxycodone market experienced a “potency arms race.” As generic manufacturers expanded their product lines after patent expiration, they competed in part by introducing higher-dose formulations, and counties more exposed to the expanding manufacturer ended up with stronger oxycodone on average. The broader point is that generic pharmaceutical competition can reshape product attributes with major externalities—even when total volume is unchanged.

That is the pitch. Then, only after this, introduce Mallinckrodt and the empirical design.

---

## 2. CONTRIBUTION CLARITY

### Contribution in one sentence
The paper's contribution is to show that generic opioid competition altered the **potency composition** of local prescription supply, not just the volume of pills, via manufacturer product-line expansion.

### Is this clearly differentiated from the closest 3–4 papers?
Partially, but not fully. The paper differentiates itself from opioid papers on marketing, regulation, and insurance by saying they focus on volume rather than composition. That is a real distinction. But it is less clear how differentiated this is from broader work on product variety, pharmaceutical competition, and vertical supply chains. Right now the paper sounds a bit like: “here is a new margin in the opioid market.” That is interesting, but not yet obviously field-defining.

The closest risk is that readers will say: “So this is a shift-share paper showing geographic heterogeneity in the rollout of high-dose generics.” That is not enough for AER unless the paper convincingly elevates the insight beyond this setting.

### World question or literature-gap question?
It is trying to answer a world question, which is good: why did some places get stronger opioids? But it keeps slipping back into literature-gap language: “the literature treats pills as homogeneous,” “no prior work examines…” That is weaker than saying: “A major piece of the opioid crisis may have operated through potency rather than quantity.”

### Could a smart economist explain what's new after reading the intro?
They could explain it, but maybe not crisply enough. The best version is: “It shows generic entry changed pill strength, not only supply volume, and that this happened through product-line strategy.” The weaker version—the one some readers will walk away with—is: “It’s another opioid supply paper with a clever exposure design.”

That ambiguity is a problem.

### What would make this contribution bigger?
Most importantly: connect potency to a larger economic question.

Specific ways:
- **Different framing:** Move from “Mallinckrodt launched some new doses” to “generic competition can worsen social harms by shifting quality on an unregulated dimension.”
- **Different outcome variable:** Even without doing a full causal second stage, the paper would feel bigger if it documented whether potency exposure predicts salient downstream market outcomes descriptively: prescribing mix, pharmacy stocking patterns, substitution away from OxyContin, or timing of local transition to illicit opioids. Right now the endpoint is potency itself, which is one step shy of the truly consequential outcome.
- **Different mechanism:** Show more clearly why firms competed on potency. Was this substitution against Purdue? A way to segment demand? A response to regulation? The paper gestures at this but does not build it into the core contribution.
- **Different comparison:** Compare this market to another generic market where entry occurs mostly on price, to make clear that opioids are special because potency is a salient attribute with externalities.
- **Different framing:** The biggest possible version is not “opioid potency changed,” but “bioequivalence-based generic regulation ignores attribute competition on socially harmful margins.”

---

## 3. LITERATURE POSITIONING

### Closest neighbors
Based on the citations and field, the closest neighbors are likely:
- **Alpert, Evans, Lieber, and Powell (2022), “Origins of the Opioid Crisis…”** on Purdue marketing / OxyContin exposure
- **Ruhm (2019)** on drivers of the opioid crisis / decomposition of overdose trends
- **Buchmueller and Carey (2020)** on prescribing regulation
- **Eichmeyer and Zhang / related pharmacy-dispensing incentive work** on opioid supply channels
- On methods/related design rhetoric: **Borusyak, Hull, and Jaravel (2022)** and **Goldsmith-Pinkham, Sorkin, and Swift (2020)** on shift-share/Bartik designs

Potentially relevant but underused:
- IO work on **generic competition, product proliferation, and non-price competition**
- Health economics on **drug formularies, physician prescribing response to product attributes, and pharmaceutical market structure**
- Regulation literature on **FDA approval, abuse-deterrent formulations, and unintended consequences of pharmaceutical regulation**

### How should the paper position itself relative to those neighbors?
- **Build on**, not attack, the opioid literature. The paper is not overturning Alpert et al.; it is adding a new supply margin.
- **Build on and extend** IO work by arguing that generic markets can feature socially costly attribute competition.
- **Be cautious** about foregrounding the shift-share literature. That is not the main conversation readers care about here. The paper should not sound like it exists to contribute a neat Bartik variant.

### Too narrow or too broad?
Currently, oddly both:
- **Too narrow** in the sense that much of the paper is about one manufacturer, one molecule, one product-line event.
- **Too broad** in the sense that it gestures toward the opioid crisis, IO, regulation, and shift-share methods all at once, without fully owning any one audience.

The right audience is probably: **health/public economics + IO/regulation**, with methods in service of that.

### What literature does the paper seem unaware of?
It seems underengaged with:
- IO on **product differentiation under regulation**
- Health econ on **drug quality/attribute choice**
- Regulatory economics on **how firms innovate around the dimensions regulators do and do not police**
- Possibly management/strategy literature on **line extension** and distribution channels, though AER doesn’t need that foregrounded

### Is the paper having the right conversation?
Not quite. The most impactful conversation is not “here is a new shift-share instrument” and not even “here is another opioid supply paper.” It is:

**When regulation constrains some dimensions of competition but ignores others, firms may compete on harmful product attributes.**

That is a much stronger conversation, and this paper could fit it.

---

## 4. NARRATIVE ARC

### Setup
The standard understanding of the first opioid wave emphasizes pill volume, marketing, prescribing, and regulation. Generic supply is implicitly treated as homogeneous.

### Tension
But pills differ in strength, and generic firms may have had incentives to compete by offering stronger formulations. If so, the geographic harms of the opioid crisis may have depended on local exposure to specific manufacturers and supply chains, not just overall prescribing volume.

### Resolution
Mallinckrodt’s expansion into higher-dose oxycodone products disproportionately increased opioid potency in counties with greater preexisting exposure to its distribution network.

### Implications
The opioid crisis was shaped by product composition as well as quantity, and generic-drug competition can generate harmful externalities on margins that standard regulation ignores.

### Does the paper have a clear arc?
There is a plausible arc, but the paper does not fully trust it. It keeps interrupting its own story with design details, first-stage diagnostics, and method-signaling. The narrative is there, but it is not being told with discipline.

At present, the paper reads somewhat like **a well-executed empirical note looking for a big-paper story**. The story it should tell is:

1. Economists focused on quantity.  
2. Potency is another economically meaningful margin.  
3. Generic competition shifted potency through product-line strategy.  
4. This reveals a broader blind spot in how we think about generic markets and regulation.

That is the narrative. Right now step 3 dominates, and steps 1, 2, and 4 are not developed enough.

---

## 5. THE "SO WHAT?" TEST

### What fact would I lead with at a dinner party?
“I have a paper showing that in the opioid crisis, generic firms didn’t just flood markets with pills—they changed how strong the pills were, and where the stronger pills went depended on preexisting supply-chain exposure.”

That is a pretty good dinner-party fact.

### Would people lean in or reach for their phones?
Initially lean in. Opioids + generic competition + potency is naturally interesting. But the next question will come fast.

### What follow-up question would they ask?
Almost certainly: **“Did that matter for overdoses or addiction?”**

And that is the paper’s central strategic vulnerability. The paper explicitly stops short of linking potency shifts to downstream health outcomes. That is intellectually defensible, but editorially costly. For AER, if the endpoint is only “potency changed,” many readers will view that as intermediate rather than decisive.

### If findings are modest, is that okay?
The effect size is modest but not trivial. Modest is fine if the conceptual point is large. The paper’s task is to convince readers that learning how competition changes the composition of supply is itself important, even without a downstream second stage.

Right now it partly succeeds, but not fully. There is still a “failed experiment” risk: it can read like a paper that wanted to say something about health harms but could only cleanly identify an intermediate input. The author needs to preempt that reaction by making a much stronger case that **potency composition is itself a first-order object** in this market.

---

## 6. STRUCTURAL SUGGESTIONS

### What would make it read better?

#### 1. Shorten the empirical-strategy material in the introduction
The introduction is too saturated with coefficient values, leave-one-state-out ranges, and placebo p-values. That is for later. The intro should establish:
- the question,
- why it matters,
- the main result,
- and the broader implication.

Right now it reads like the paper is trying to prove credibility before it has earned reader interest.

#### 2. Front-load the conceptual contribution, not the diagnostics
The paper should get to the big idea faster:
- volume vs composition,
- generic competition on potency,
- regulatory blind spots.

Those are the hooks.

#### 3. Relegate some of the validation rhetoric
Items like “55/55 state-drops same sign” and the Young consistency benchmark are too inside-baseball for the current draft and make the paper sound defensive. This belongs later, and in a more restrained tone.

#### 4. Expand the institutional/IO mechanism section
The institutional background should do more work:
- Why would a generic firm introduce these strengths?
- Who demanded them?
- How did this compete with branded OxyContin?
- Why did distribution networks make geography persistent?

That mechanism is more important for positioning than another specification table.

#### 5. Tighten the methods contribution claim
The sentence claiming contribution to the shift-share literature is a mistake strategically. It dilutes the main contribution. Unless the paper is genuinely methodologically novel in a way methods readers will care about, this should be demoted or dropped.

#### 6. The conclusion should do more than summarize
The conclusion is decent, but it could be sharper about the general lesson:
- Generic markets are not always benign price-competition stories.
- Regulation can miss harmful dimensions of product differentiation.
- Economists should treat product composition, not just volume, as endogenous.

That is more valuable than restating the findings.

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

This is mainly a **framing and ambition problem**, with some **scope** issues.

The science may be competent, but in current form the paper feels like a strong field-journal paper rather than an AER paper. Why? Because the result is narrow unless the author persuades readers that it changes how we think about a much bigger class of markets.

### What is the gap?
- **Not mainly identification** for present purposes.
- **Not mainly writing quality**; the prose is actually fairly strong.
- **Mainly:** the paper has not yet claimed enough conceptual territory.

At the moment, the implied contribution is:
> “One manufacturer’s product expansion increased local oxycodone potency.”

For AER, the contribution needs to sound more like:
> “Generic competition can increase social harm by shifting product attributes along unregulated margins; the opioid market reveals this mechanism starkly.”

That is a materially bigger claim.

### Is it a novelty problem?
Somewhat. “Another opioid supply paper” is a real risk. The novelty is the potency margin. That novelty is real, but it needs to be made to feel central rather than incremental.

### Is it a scope problem?
Yes. The paper likely needs either:
- broader evidence on mechanism and market structure, or
- stronger integration with downstream implications, even if not a full causal second stage.

### Is it an ambition problem?
Yes. The paper is careful and somewhat conservative in what it claims. That caution may be scientifically appropriate, but editorially it leaves value on the table.

### Single most impactful advice
**Reframe the paper around a general economic insight—firms compete on harmful product attributes when regulation ignores those dimensions—rather than around a single manufacturer event in the opioid market.**

That one change would clarify the audience, raise the stakes, and make the existing evidence feel like a test of a broader idea rather than a niche historical episode.

---

### Strategic Assessment

- **Current framing quality:** Adequate
- **Contribution clarity:** Somewhat fuzzy
- **Literature positioning:** Could be stronger
- **Narrative arc:** Serviceable
- **AER distance:** Medium
- **Single biggest improvement:** Recast the paper as evidence on harmful attribute competition in regulated generic markets, with opioids as the leading application rather than the whole story.